NCT05978141

A Registry for People With T-cell Lymphoma

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Conditions

• T-cell Lymphoma
• NK-Cell Lymphoma
• T-cell Prolymphocytic Leukemia
• T-cell Large Granular Lymphocytic Leukemia
• Chronic Lymphoproliferative Disorder of NK Cells
• Aggressive NK-cell Leukemia
• Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)
• Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood
• Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form
• Hydroa Vacciniforme-Like Lymphoproliferative Disorder
• Adult T-cell Leukemia/Lymphoma
• Extranodal NK/T-cell Lymphoma, Nasal Type
• Enteropathy-associated T-cell Lymphoma
• Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
• Intestinal T-Cell Lymphoma, Not Otherwise Specified
• Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
• Hepatosplenic T-cell Lymphoma
• Subcutaneous Panniculitis-Like T-Cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome
• Primary Cutaneous Anaplastic Large Cell Lymphoma
• Primary Cutaneous T-cell Lymphoma
• Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
• Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma
• Peripheral T-Cell Lymphoma, Not Otherwise Specified
• Angioimmunoblastic T-cell Lymphoma
• Follicular T-Cell Lymphoma
• Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
• Anaplastic Large Cell Lymphoma, ALK-Positive
• Anaplastic Large Cell Lymphoma, ALK-negative
• Breast Implant-Associated Anaplastic Large Cell Lymphoma

Interventions

Type	Name	Description
OTHER	Optional Blood Sample and Nail Sample	Participants may provide optional research blood and nail samples for biobanking and future use

Timeline

• Start date: 2023-07-27
• Primary completion: 2030-07-27
• Completion: 2030-07-27
• First posted: 2023-08-07
• Last updated: 2025-05-21

Locations

26 sites across 1 country: United States